ANEW Medical’s (WENA) Breakthrough in Gene Therapy Leads To Surge in Stock Prices

In the bustling landscape of biopharmaceutical innovations, ANEW Medical Inc. (NASDAQ: WENA) stands out with its pioneering strides in the realm of neurological and age-related disorders. Recently, the company experienced a notable surge in its stock value, closing at $3.62, which marks a dramatic increase of 119.39%. This was followed by a slight decrease after hours. Despite these fluctuations, the excitement around ANEW Medical is palpable, fueled by a series of groundbreaking developments.

A Milestone in Intellectual Property

ANEW Medical has recently been granted a crucial patent in Europe (EP3377091B1) for its innovative use of the secreted Klotho gene sequence and gene delivery systems. This patent covers the treatment of cognitive decline, dementia, and other neurodegenerative diseases—conditions that afflict millions worldwide. The patent was acquired from a collaborative licensing agreement with Universitat Autònoma de Barcelona and Institució Catalana de Recerca i Estudis Avançats, highlighting ANEW’s commitment to global research collaborations.

Global Expansion and Development

The company is not new to receiving patents; earlier this year, it secured approvals in China and Hong Kong, setting the stage for its expansion into the Asian markets. With these patents, ANEW plans to initiate product development that could revolutionize the approach to treating neurodegenerative diseases.

Innovative Approaches to Neurodegenerative Diseases

Dr. Joseph Sinkule, Founder and CEO of ANEW Medical, emphasizes the potential of the company’s therapy programs. ANEW’s focus on the secreted Klotho RNA splice variant (s-KL), primarily produced in the human brain, positions it at the forefront of neuroscientific research. This protein plays a critical role in maintaining normal brain function and could be a key player in combating diseases like Alzheimer’s, Parkinson’s, Huntington’s, and ALS.

Forward-Looking Strategies

Looking ahead, ANEW Medical is exploring further diagnostics and therapeutics utilizing the s-KL protein. The company is keen on diving deeper into the interactions of this protein with other vital human proteins and genes of interest, which could lead to significant advancements in medical products and treatments.

About ANEW Medical

ANEW Medical Inc. is a visionary biopharmaceutical company focused on developing novel therapies for CNS diseases and aging-related conditions. With exclusive worldwide rights to its proprietary products based on the Klotho gene, ANEW Medical is exploring cell and gene therapies that promise to mitigate the effects of aging and chronic neurological diseases. For more information about ANEW and its innovative solutions, visit

The journey of ANEW Medical highlights a promising trajectory in the field of biopharmaceuticals, driven by scientific excellence and a dedication to improving human health across the globe. As the company expands its footprint internationally, the healthcare community eagerly anticipates the positive impacts its research will bring to the forefront of medical science.